Research from Water Tower Research, Water Tower Research

Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Research from Water Tower Research

Equity Research Firm

Equity Bottom-Up

<ul><li>Eli Lilly courting AtaiBeckley. Eli Lilly (NYSE: LLY) has announced that it intends to acquire AtaiBeckley (NASDAQ: ATAI) in a deal worth up to $3.8 billion.</li><li>The run time to complete is short, with the transaction expected to close this quarter. </li><li>Under the terms of the definitive agreement, LLY will pay ATAI shareholders $6.75 per share or $2.8 billion in upfront payment plus up to $2.50 per share of additional cash payments worth up to $1 billion in the form of a contingent value right (CVR). </li></ul>

Eli Lilly courting AtaiBeckley. Eli Lilly (NYSE: LLY) has announced that it intends to acquire AtaiBeckley (NASDAQ: ATAI) in a deal worth up to $3.8 billion.The run time to complete is short, with the transaction expected to close this quarter. Under the terms of the definitive agreement, LLY will pay ATAI shareholders $6.75 per share or $2.8 billion in upfront payment plus up to $2.50 per share of additional cash payments worth up to $1 billion in the form of a contingent value right (CVR). 

Biotech M&A : Psychedelics' Coming as Eli Lilly's AtaiBeckley Acquisition Sets a Valuation Benchmark

ATAI Life Sciences NV

Biotech M&A : Psychedelics' Coming as Eli Lilly's AtaiBeckley Acquisition Sets a Valuation Benchmark